Monitoring Your Child: Risks and Urgent Signs
At a Glance
Children with Juvenile Paget disease need specialist monitoring of bones, calcium, growth, hearing, and vision. Seek emergency care for severe cramps or tingling after an infusion, extreme thirst or lethargy after denosumab is stopped or delayed, suspected fractures, or sudden neurologic changes.
Caring for a child with Juvenile Paget Disease (JPD) requires a transition from the diagnostic phase to a long-term “watchful care” phase. While treatment is highly effective at managing the condition, it requires ongoing monitoring to ensure the bones remain stable and that the medication itself is not causing unexpected side effects.
Symptoms That Are Often Less Urgent
It is common for children with JPD to experience occasional bone “aches” or mild fatigue, especially as they grow or after physical activity [1]. These symptoms can often be discussed at your next routine follow-up. However, fatigue is non-specific, and you should contact your clinical team promptly if your child develops new persistent pain, swelling, reduced use of a limb, or a fever after an infusion.
When to Seek Emergency Care
Because JPD treatments are powerful, you must be able to recognize specific “red flag” symptoms that require immediate evaluation at an emergency department.
1. Severe Low Calcium (Hypocalcemia)
This is most likely to occur in the days following an intravenous (IV) bisphosphonate infusion, especially the first dose [2]. Go to the ER immediately if you notice:
- Muscle Irritability: Uncontrollable muscle cramps, “twitching,” or stiffness (tetany) [3].
- Tingling or Numbness: Usually felt around the mouth or in the fingertips and toes [3].
- Neurological Changes: Sudden confusion, extreme irritability, or a seizure [4][3].
- Fainting or Heart Palpitations: Severe calcium drops can affect the heart’s rhythm [4].
2. Rebound High Calcium (Hypercalcemia)
If your child has been treated with denosumab and the medication is stopped or delayed, their bone turnover can “rebound,” causing blood calcium to rise dangerously high [5][6]. This typically happens 2 to 9 months after the last dose [5]. Seek emergency care for:
- Persistent vomiting or dehydration [7].
- Intense thirst and frequent urination [8].
- Extreme lethargy or difficulty waking up [7].
3. Suspected Fractures or Neurological Compression
In a child with JPD, new focal pain (pain centered on one specific spot), swelling, deformity, refusal to bear weight, or inability to use a limb should prompt urgent evaluation for a fracture, even after minor trauma.
Additionally, thickening of bones can sometimes press on nerves or the spinal cord [9][10]. Seek urgent care for:
- Sudden weakness in the legs or difficulty walking.
- New loss of bowel or bladder control.
- A “thunderclap” or unusually severe headache [11].
- Sudden loss of vision or hearing [10][12].
Individualized Surveillance Plans
Because JPD is a complex condition, your child will need a “surveillance team” of specialists. There is no single established schedule for every child; monitoring typically involves a specialist-directed plan:
- Laboratory Safety Checks: Frequent blood tests to monitor calcium, phosphate, magnesium, vitamin D, and kidney function, as well as alkaline phosphatase (ALP) and other bone-turnover markers to see if the disease is “reactivating” [1][13].
- Hearing (Audiology): Comprehensive hearing tests are essential as directed by your specialist, as JPD can cause progressive hearing loss that treatment may not always prevent [13][14].
- Vision (Ophthalmology): Eye exams are recommended to look for retinal changes based on clinical judgment [13][12].
- Heart and Vessels (Cardiovascular): Periodic imaging (like ultrasounds or CT scans) is not universally established, but may be used to check for calcium build-up in the arteries or aneurysms if recommended by a specialist, carefully weighing radiation risks of CT [13][15].
- Growth Tracking: Because long-term treatment can sometimes impact a child’s growth velocity, your doctor will carefully plot their height and weight on specialized growth charts [16][14].
Potential Complications and Uncertainties
- Ear Cartilage Changes: Some patients have developed “stiff” or hardened ears (auricular cartilage ossification). While reported in patients with prolonged bisphosphonate exposure, it is an uncommon, uncertain association, and attribution to the medication rather than the disease itself is not definitively established [17].
- Breathing and Intubation: In rare cases, JPD can affect the cartilage in the airway. If your child ever needs surgery, it is vital to tell the anesthesiologist they have JPD [17].
By staying vigilant for these signs and keeping a consistent schedule of specialist visits, you can help ensure your child receives the full benefit of their treatment while minimizing risks.
Common questions in this guide
Which symptoms after a bisphosphonate infusion are an emergency?
What should I watch for if denosumab is stopped or delayed?
When does bone pain in a child with Juvenile Paget disease need urgent evaluation?
What follow-up monitoring does a child with Juvenile Paget disease need?
Which neurologic changes require emergency care?
How is hearing loss monitored in a child with Juvenile Paget disease?
Why must the anesthesiologist know about Juvenile Paget disease before surgery?
Get notified when new evidence is published on Juvenile Paget disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Clinical course in two children with Juvenile Paget's disease during long-term treatment with intravenous bisphosphonates.
Höppner J, Steff K, Misof BM, et al.
Bone reports 2021; (14()):100762 doi:10.1016/j.bonr.2021.100762.
PMID: 33850973 - 2
Acquired resistance to pamidronate treated effectively with zoledronate in juvenile Paget's disease.
Gonc EN, Ozon A, Buyukyilmaz G, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2018; (29(6)):1471-1474 doi:10.1007/s00198-018-4443-7.
PMID: 29502293 - 3
Hypocalcemic disorders.
Bove-Fenderson E, Mannstadt M
Best practice & research. Clinical endocrinology & metabolism 2018; (32(5)):639-656 doi:10.1016/j.beem.2018.05.006.
PMID: 30449546 - 4
Severe pediatric hypocalcemia in Vietnam: etiologic profile, clinical outcomes and risk factors in 246 cases.
Nguyen TT, Dang GTK, Bui PT, et al.
Frontiers in endocrinology 2026; (17()):1701713 doi:10.3389/fendo.2026.1701713.
PMID: 41704483 - 5
Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review.
Schmitt L, Theiler-Schwetz V, Sadoghi P, et al.
Archives of endocrinology and metabolism 2024; (68()):e240035 doi:10.20945/2359-4292-2024-0035.
PMID: 39529981 - 6
Hypercalcemia in children induced by denosumab: a case report and an analysis of the FDA adverse event reporting system database.
Chen Y, Fang C, Yang Z, et al.
Expert opinion on drug safety 2025; (24(6)):719-730 doi:10.1080/14740338.2024.2379446.
PMID: 39007894 - 7
Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
Uday S, Gaston CL, Rogers L, et al.
The Journal of clinical endocrinology and metabolism 2018; (103(2)):596-603 doi:10.1210/jc.2017-02025.
PMID: 29211870 - 8
Successful denosumab treatment for central giant cell granuloma in a 9-year-old child.
Mariz BALA, Migliorati CA, Alves FA, et al.
Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry 2021; (41(4)):519-525 doi:10.1111/scd.12588.
PMID: 33760257 - 9
Spinal manifestations of Paget's disease: Case presentation and systematic review.
Eissa AT, Pedro KM, Gao AF, Fehlings MG
Brain & spine 2025; (5()):105889 doi:10.1016/j.bas.2025.105889.
PMID: 41439173 - 10
Paget's disease of bone in a North African population: clinical, imaging, and therapeutic insights from a Moroccan case series.
Ridah W, Nassar K, Ajerouassi A, et al.
Clinical rheumatology 2026; (45(3)):1899-1905 doi:10.1007/s10067-026-07935-0.
PMID: 41526553 - 11
Headache and Status Epilepticus Reveal Paget's Disease of the Bone.
Ouhabi D, Tibar H, Benomar A, et al.
Cureus 2024; (16(5)):e60588 doi:10.7759/cureus.60588.
PMID: 38894759 - 12
Loss of Functional Osteoprotegerin: More Than a Skeletal Problem.
Grasemann C, Unger N, Hövel M, et al.
The Journal of clinical endocrinology and metabolism 2017; (102(1)):210-219 doi:10.1210/jc.2016-2905.
PMID: 27809640 - 13
Juvenile Paget disease.
Polyzos SA, Cundy T, Mantzoros CS
Metabolism: clinical and experimental 2018; (80()):15-26 doi:10.1016/j.metabol.2017.10.007.
PMID: 29080812 - 14
Juvenile Paget's Disease: Report of a successful treatment throughout the complete growth of a patient with a missense TNFRSF11B mutation.
Prata AR, Saraiva J, Salgado M, Estanqueiro P
Joint bone spine 2021; (88(6)):105243 doi:10.1016/j.jbspin.2021.105243.
PMID: 34166796 - 15
Early-onset juvenile Paget disease associated with a homozygous intronic TNFRSF11B variant: a 2-year follow-up.
Meral R, Gökoğlu M
Journal of pediatric endocrinology & metabolism : JPEM 2026; doi:10.1515/jpem-2026-0332.
PMID: 42528457 - 16
Rhizomelia and Impaired Linear Growth in a Girl with Juvenile Paget Disease: The Natural History of the Condition.
Höppner J, Steff K, Lobert F, et al.
Hormone research in paediatrics 2021; (94(3-4)):151-158 doi:10.1159/000517164.
PMID: 34261073 - 17
Auricular ossification: A newly recognized feature of osteoprotegerin-deficiency juvenile Paget disease.
Gottesman GS, Madson KL, McAlister WH, et al.
American journal of medical genetics. Part A 2016; (170A(4)):978-85 doi:10.1002/ajmg.a.37536.
PMID: 26762549
This page is for informational purposes only and does not constitute medical advice about your child's Juvenile Paget disease. Contact your child's care team or emergency services for urgent symptoms and follow the specialist's monitoring plan.